SCHEMBL3343901

SCHEMBL3343901

O=C(NNc1nc(-c2ccccc2)cs1)c1ccccc1F

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.77
KMT2A Q03164 8/20 0.77
RAB9A P51151 3/20 0.77
NPC1 O15118 2/20 0.77
MAPT P10636 9/20 0.70
KDM4E B2RXH2 8/20 0.70
GAA P10253 7/20 0.70
ALDH1A1 P00352 4/20 0.70
LMNA P02545 4/20 0.70
HTT P42858 5/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
TDP1 Q9NUW8 3/20 0.70
ROCK1 Q13464 1/20 0.66
MAPK1 P28482 3/20 0.64
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
GFER P55789 1/20 0.58
ELOVL1 Q9BW60 1/20 0.58
SCD O00767 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338830 0.97 MEN1 (0.73) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3338847 0.90 MEN1 (0.63) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3338172 0.87 MEN1 (0.80) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3337378 0.84 CSNK2A1 (0.62) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3344724 0.82 KDM4E (1.00) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL3341776 0.80 MAPT (0.89) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL13357590 0.80 ROCK1 (1.00) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3338134 0.78 KDM4E (0.85) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL3335896 0.78 MAPT (1.00) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3338748 0.77 MAPT (0.82) MEN1KMT2ANPC1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MEN1 1886/4885KMT2A 3492/4885RAB9A 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.